210 related articles for article (PubMed ID: 21599432)
21. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
[TBL] [Abstract][Full Text] [Related]
22. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
23. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
[TBL] [Abstract][Full Text] [Related]
24. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
25. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
26. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Peng CT; Chow KC; Chen JH; Chiang YP; Lin TY; Tsai CH
Eur J Haematol; 2003 Jun; 70(6):392-7. PubMed ID: 12756022
[TBL] [Abstract][Full Text] [Related]
27. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
[TBL] [Abstract][Full Text] [Related]
28. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
[TBL] [Abstract][Full Text] [Related]
29. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
30. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
31. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
32. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
[TBL] [Abstract][Full Text] [Related]
33. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
34. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
Tourkantoni N; Athanassiou-Metaxa M; Zafiriou D; Tzimouli V; Economou M; Taparkou A; Perifanis V; Kanakoudi-Tsakalidou F
Hemoglobin; 2008; 32(1-2):35-40. PubMed ID: 18274981
[TBL] [Abstract][Full Text] [Related]
35. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Huang YC; Chang JS; Wu KH; Peng CT
Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
[TBL] [Abstract][Full Text] [Related]
36. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
[TBL] [Abstract][Full Text] [Related]
37. comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
Perifanis V; Christoforidis A; Vlachaki E; Tsatra I; Spanos G; Athanassiou-Metaxa M
Int J Hematol; 2007 Dec; 86(5):385-9. PubMed ID: 18192103
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Piga A; Gaglioti C; Fogliacco E; Tricta F
Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268
[TBL] [Abstract][Full Text] [Related]
39. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Origa R; Danjou F; Cossa S; Matta G; Bina P; Dessì C; Defraia E; Foschini ML; Leoni G; Morittu M; Galanello R
Br J Haematol; 2013 Nov; 163(3):400-3. PubMed ID: 24033185
[TBL] [Abstract][Full Text] [Related]
40. T2* magnetic resonance and myocardial iron in thalassemia.
Pennell DJ
Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
